4CB 1
Alternative Names: 4CB-1; Alpha 4CB-1.1; α4CB-1.1Latest Information Update: 02 Apr 2024
At a glance
- Originator 4C Biomed
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 02 Apr 2024 Adverse events and pharmacodynamics data from a preclinical trial in Cancer released by 4C Biomed (4C Biomed pipeline, April 2024)
- 02 Apr 2024 4C Biomed plans a clinical trial for Cancer in 2025 (4C Biomed Pipeline, April 2024)
- 29 Sep 2021 Alpha 4CB 1.1 is available for licensing as of 29 Sep 2021. https://4cbiomed.com/collaborations/